Clinical Trials Search Results

1.

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CSOM230B2412, NCI-2017-01247, NCT01794793

2.

Stereotactic Body Radiation Therapy in Treating Patients with Pancreatic or Ampulla of Vater Cancer That Cannot Be Removed by Surgery

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16866B, NCI-2015-01656, NCT01342354

3.

Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 11I03, NCI-2011-02939, NCT01465659

4.

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients with Pancreatic Neuroendocrine Tumors

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201303150, NCI-2013-00641, NCT01784861

5.

Regorafenib in Treating Patients with Advanced or Metastatic Neuroendocrine Tumors

Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-14-3, NCI-2014-01996, HS-14-00583, NCT02259725

6.

Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas

Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 150040, 339636, P141605, NCT02315625

7.

Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18141, NCI-2015-01782, 15.04.0041, NCT02575300

8.

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067

9.

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CPDR001E2201, NCI-2017-00420, 2016-002522-36, NCT02955069

10.

Sapanisertib and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9585, NCI-2014-01107, 2013-0665, NCT02159989

11.

Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors

Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, 17-C-0012, NCT02631733

12.

TAS-102 and Temozolomide in Treating Patients with Metastatic Neuroendocrine Tumors

Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UW16034, NCI-2016-01567, NCT02943733

13.

Veliparib, Capecitabine, and Temozolomide in Treating Patients with Advanced, Metastatic, and Recurrent Neuroendocrine Tumor That Cannot Be Removed by Surgery

Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 19 and over
Trial IDs: VICC GI 14134, NCI-2016-01044, NCT02831179

14.

Collection of Tumor Samples in Identifying Potential Predictors of Response to Novel Therapies in Patients with Metastatic Pancreatic Neuroendocrine Tumors

Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 12-058, NCI-2016-01730, NCT01603004

15.

68Ga-DOTA-JR11and 177Lu-DOTA-JR11 PET/CT in Diagnosing and Treating Patients with Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 15-161, NCI-2015-02110, NCT02609737

Clinical Trials Search Results

Results 1-15 of 15 for your search: